The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated non small cell lung cancer (NSCLC), enabling five-minute administration with fewer infusion reactions. I ...
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or ...
Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab ...
FDA has approved AKEEGA (niraparib and abiraterone) as the first precision therapy for BRCA2+ metastatic castration-sensitive ...
An international study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on ...
Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell ...
Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...
New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback